TDC
RCEL icon

Thompson Davis & Co’s Avita Medical RCEL Stock Holding History

Thompson Davis & Co’s Portfolio RCEL Stock Details RCEL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$128K Sell
31,090
-7,960
-20% -$34.3K 0.08% 150
2026
Q1 		$144K Buy
+39,050
New +$164K 0.1% 122

Other funds holding RCEL

Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
NA
NewEdge Advisors New Orleans, Louisiana $33.6B AUM 31.03% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $23.2B AUM 40.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Thompson Davis & Co's RCEL Position: Q2 2026 in Review

Thompson Davis & Co reduced its Avita Medical (RCEL) stake by 20% in Q2 2026, selling an estimated $34.3K and leaving 31,090 shares worth $128K. The position accounts for 0.08% of the portfolio, ranked #150.

Thompson Davis & Co first reported a position in RCEL in Q1 2026 and has held it in 2 quarters since. The position peaked at $144K in Q1 2026. 73 funds tracked by Wall St. Rank hold RCEL as of Q2 2026.

  • Thompson Davis & Co held 31,090 shares of Avita Medical worth $128K as of Q2 2026.
  • Thompson Davis & Co sold 7,960 Avita Medical shares in Q2 2026, an estimated $34.3K.
  • Avita Medical made up 0.08% of Thompson Davis & Co's portfolio in Q2 2026, its #150 holding.
  • Thompson Davis & Co first reported a position in Avita Medical in Q1 2026 and has held it in 2 quarters since.
  • Thompson Davis & Co's Avita Medical position peaked at $144K in Q1 2026.
  • 73 funds tracked by Wall St. Rank held Avita Medical as of Q2 2026.

Based on Thompson Davis & Co's 13F filing for Q2 2026, filed 29 Jul 2026.